Health Economics›Allogeneic HSCT›Reduced-intensity conditioning (RIC), all lines of therapy

Reduced-intensity conditioning (RIC), all lines of therapy

Allogeneic HSCT · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Fludarabine, Busulfan, ATG Partial	—	—	—	—	—	—	—	—
Cyclophosphamide and Fludarabine (FluCy) Partial	—	—	—	—	—	—	—	—
Fludarabine, Melphalan, Alemtuzumab Partial	—	—	—	—	—	—	—	—

3 of 3 regimens shown